Fulfill demands for more stringent HOS analysis
Assessment of HOS based on CD data has for many years been based on simple graphical comparisons. Now, the Chirascan Q100 system for CD analysis allows for a quantitative approach to rigorous statistical analysis as recommended by the Office of Biostatistics and Office of Biotechnology Products (CDER/FDA).
Capable of detecting minor differences in secondary and tertiary structure, and offering high reproducibility thanks to defined experimental procedures using liquid handling, the system generates high-quality raw data to enable quantification of similarities and differences and confirm their statistical significance. Previously subjective HOS comparisons now contribute to objective, informed decision making.
